Black Diamond Therapeutics (BDTX)
Black Diamond Therapeutics on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
4.8M
Short interest
settlement 2026-09-30
7.3
Days to cover
-2.8 days vs prior
30.0%
Short share of volume
2026-10-09
213
Fails to deliver
settlement 2026-09-10
Wed 2 Dec
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in BDTX is 4,775,586 shares, down 1,343,430 shares over the last month. Over the last 48 readings it ranged from 3,754,051 shares (15 January 2026) to 10,174,767 shares (31 March 2025). At the reported average volume of 654K shares a day that is 7.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/bdtx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 4,775,586 | -7.2% | 653,622 | 7.31 |
| 2026-09-15 | 5,147,935 | -15.9% | 508,311 | 10.13 |
| 2026-08-31 | 6,119,016 | -1.1% | 562,866 | 10.87 |
| 2026-08-14 | 6,185,629 | +5.5% | 596,806 | 10.36 |
| 2026-07-31 | 5,862,939 | +0.2% | 674,266 | 8.70 |
| 2026-07-15 | 5,851,617 | +30.0% | 1,568,961 | 3.73 |
| 2026-06-30 | 4,502,074 | -9.7% | 2,547,230 | 1.77 |
| 2026-06-15 | 4,984,059 | -17.4% | 1,346,464 | 3.70 |
| 2026-05-29 | 6,033,281 | +14.5% | 3,536,856 | 1.71 |
| 2026-05-15 | 5,267,173 | +17.6% | 957,858 | 5.50 |
| 2026-04-30 | 4,477,803 | -18.2% | 851,743 | 5.26 |
| 2026-04-15 | 5,473,560 | +8.0% | 819,082 | 6.68 |
| 2026-03-31 | 5,067,871 | +0.2% | 489,293 | 10.36 |
| 2026-03-13 | 5,058,624 | +9.4% | 777,893 | 6.50 |
| 2026-02-27 | 4,625,166 | +12.1% | 433,974 | 10.66 |
| 2026-02-13 | 4,127,917 | -0.1% | 758,777 | 5.44 |
| 2026-01-30 | 4,133,091 | +10.1% | 869,504 | 4.75 |
| 2026-01-15 | 3,754,051 | -0.9% | 931,119 | 4.03 |
| 2025-12-31 | 3,787,526 | -39.9% | 911,959 | 4.15 |
| 2025-12-15 | 6,298,943 | +2.9% | 2,194,673 | 2.87 |
| 2025-11-28 | 6,123,148 | -3.7% | 1,035,658 | 5.91 |
| 2025-11-14 | 6,356,283 | +2.9% | 1,287,188 | 4.94 |
| 2025-10-31 | 6,174,621 | -0.4% | 714,322 | 8.64 |
| 2025-10-15 | 6,198,261 | -2.1% | 1,013,800 | 6.11 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of BDTX volume is 30.0%, down 27.8 points over the last five sessions. Over the last 30 readings it ranged from 30.0% (9 October 2026) to 73.1% (18 September 2026). The latest reading sits at the bottom of that range. The latest reading is 28.7 points below the 30-session average of 58.7%, on 143K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 43K | 143K | 30.0% | 0 |
| 2026-10-08 | 125K | 241K | 52.1% | 501 |
| 2026-10-07 | 100K | 179K | 56.1% | 1,884 |
| 2026-10-06 | 181K | 281K | 64.2% | 84 |
| 2026-10-05 | 93K | 149K | 62.6% | 0 |
| 2026-10-02 | 77K | 134K | 57.8% | 0 |
| 2026-10-01 | 50K | 96K | 51.8% | 0 |
| 2026-09-30 | 78K | 142K | 55.3% | 0 |
| 2026-09-29 | 85K | 156K | 54.2% | 5 |
| 2026-09-28 | 166K | 266K | 62.4% | 0 |
| 2026-09-25 | 106K | 148K | 71.9% | 628 |
| 2026-09-24 | 106K | 154K | 68.6% | 11,091 |
| 2026-09-23 | 151K | 210K | 72.2% | 13 |
| 2026-09-22 | 89K | 231K | 38.6% | 7 |
| 2026-09-21 | 219K | 311K | 70.5% | 0 |
| 2026-09-18 | 136K | 187K | 73.1% | 4,500 |
| 2026-09-17 | 94K | 203K | 46.2% | 133 |
| 2026-09-16 | 142K | 215K | 65.9% | 2,400 |
| 2026-09-15 | 55K | 101K | 54.4% | 612 |
| 2026-09-14 | 78K | 114K | 68.4% | 0 |
| 2026-09-11 | 128K | 229K | 56.1% | 6,400 |
| 2026-09-10 | 224K | 314K | 71.5% | 96 |
| 2026-09-09 | 86K | 130K | 66.6% | 1,200 |
| 2026-09-08 | 71K | 119K | 59.6% | 0 |
| 2026-09-04 | 37K | 68K | 54.8% | 0 |
| 2026-09-03 | 88K | 139K | 62.7% | 0 |
| 2026-09-02 | 50K | 92K | 55.0% | 0 |
| 2026-09-01 | 90K | 245K | 36.9% | 0 |
| 2026-08-31 | 108K | 192K | 56.4% | 0 |
| 2026-08-28 | 138K | 214K | 64.6% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 10 September 2026, the fails-to-deliver balance in BDTX is 213 shares, down 2,438 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (22 July 2026) to 176,382 shares (29 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-10 | 213 | $2.10 | $447 |
| 2026-09-08 | 2,651 | $2.12 | $6K |
| 2026-09-03 | 2,523 | $2.14 | $5K |
| 2026-08-26 | 198 | $2.24 | $444 |
| 2026-08-24 | 750 | $2.21 | $2K |
| 2026-08-21 | 305 | $2.15 | $656 |
| 2026-08-19 | 3,286 | $2.06 | $7K |
| 2026-08-14 | 226 | $2.02 | $457 |
| 2026-08-12 | 21 | $2.09 | $44 |
| 2026-08-11 | 4,801 | $1.98 | $10K |
| 2026-08-10 | 4,334 | $1.95 | $8K |
| 2026-08-05 | 2,880 | $1.78 | $5K |
| 2026-08-04 | 1,429 | $1.74 | $2K |
| 2026-07-22 | 2 | $1.87 | $4 |
| 2026-07-17 | 1,861 | $1.81 | $3K |
| 2026-07-10 | 694 | $1.88 | $1K |
| 2026-07-08 | 107 | $2.08 | $223 |
| 2026-07-07 | 11,971 | $1.97 | $24K |
| 2026-07-01 | 3,906 | $1.85 | $7K |
| 2026-06-30 | 25,151 | $1.75 | $44K |
| 2026-06-29 | 176,382 | $1.71 | $302K |
| 2026-06-22 | 117,793 | $1.66 | $196K |
| 2026-06-18 | 21,601 | $1.67 | $36K |
| 2026-06-02 | 4,761 | $2.26 | $11K |
| 2026-05-26 | 8,260 | $2.28 | $19K |
| 2026-05-22 | 5,970 | $3.55 | $21K |
| 2026-05-21 | 14,034 | $3.60 | $51K |
| 2026-05-20 | 21 | $3.00 | $63 |
| 2026-05-18 | 14 | $2.75 | $39 |
| 2026-05-13 | 25 | $2.83 | $71 |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONNo open-market insider trades were reported for BDTX in the last 90 days. The most recent filings are listed below. Latest filing: Raman Prakash (Director) on 2026-09-18.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | Raman Prakash | Director | Grant | 7K | $1.93 | $13K | 52K |
| 2026-09-18 | Behbahani Ali | Director | Grant | 8K | $1.93 | $15K | 110K |
| 2026-06-19 | Raman Prakash | Director | Grant | 8K | $1.66 | $13K | 45K |
| 2026-06-19 | Behbahani Ali | Director | Grant | 9K | $1.66 | $15K | 103K |
| 2026-03-20 | Raman Prakash | Director | Grant | 6K | $2.15 | $13K | 37K |
| 2026-03-20 | Behbahani Ali | Director | Grant | 7K | $2.15 | $15K | 94K |
| 2025-12-12 | Raman Prakash | Director | Grant | 5K | $2.76 | $13K | 31K |
| 2025-12-12 | Behbahani Ali | Director | Grant | 5K | $2.76 | $14K | 87K |
| 2025-09-19 | Raman Prakash | Director | Grant | 4K | $3.35 | $13K | 26K |
| 2025-09-19 | Behbahani Ali | Director | Grant | 4K | $3.35 | $14K | 81K |
| 2025-06-20 | Raman Prakash | Director | Grant | 6K | $2.33 | $13K | 23K |
| 2025-06-20 | Behbahani Ali | Director | Grant | 6K | $2.33 | $14K | 77K |
| 2025-03-21 | Raman Prakash | Director | Grant | 7K | $1.88 | $13K | 17K |
| 2025-03-21 | Behbahani Ali | Director | Grant | 8K | $1.88 | $14K | 71K |
| 2025-03-19 | BIOTECH GROWTH N V | 10% owner | Sell | 1.0M | $2.31 | $2.3M | 6.2M |
| 2025-03-19 | BIOTECH GROWTH N V | TenPercentOwner | Sell | 584K | $1.95 | $1.1M | 3.2M |
| 2025-03-19 | BIOTECH GROWTH N V | TenPercentOwner | Sell | 300K | $1.94 | $582K | 7.2M |
| 2025-03-19 | BIOTECH GROWTH N V | TenPercentOwner | Sell | 2.0M | $2.00 | $4.0M | 4.2M |
| 2025-03-19 | BIOTECH GROWTH N V | TenPercentOwner | Sell | 1.0M | $2.07 | $2.1M | 7.5M |
| 2025-03-19 | BIOTECH GROWTH N V | TenPercentOwner | Sell | 500K | $2.12 | $1.1M | 2.7M |
| 2025-03-19 | BIOTECH GROWTH N V | TenPercentOwner | Sell | 400K | $2.09 | $836K | 3.8M |
| 2025-01-30 | Hatzis-Schoch Brent | SEE REMARKS | Grant | 75K | $0.00 | $0 | 83K |
| 2025-01-30 | Jones Erika | SEE REMARKS | Grant | 75K | $0.00 | $0 | 85K |
| 2025-01-30 | Buck Elizabeth | CHIEF SCIENTIFIC OFFICER | Grant | 75K | $0.00 | $0 | 170K |
| 2025-01-30 | Yurasov Sergey | CHIEF MEDICAL OFFICER | Grant | 75K | $0.00 | $0 | 75K |
| 2025-01-30 | Velleca Mark A. | PRESIDENT & CEO | Grant | 75K | $0.00 | $0 | 122K |
| 2024-12-13 | Campbell Shannon | Director | Grant | 5K | $2.50 | $11K | 9K |
| 2024-12-13 | Raman Prakash | Director | Grant | 5K | $2.50 | $13K | 10K |
| 2024-12-13 | Behbahani Ali | Director | Grant | 6K | $2.50 | $14K | 63K |
| 2024-09-20 | Raman Prakash | Director | Grant | 3K | $4.78 | $13K | 5K |
| 2024-09-20 | Campbell Shannon | Director | Grant | 2K | $4.78 | $11K | 4K |
| 2024-09-20 | Behbahani Ali | Director | Grant | 3K | $4.78 | $14K | 58K |
| 2024-08-28 | Versant Voyageurs I Parallel, L.P. | TenPercentOwner | Sell | 222K | $6.32 | $1.4M | 3.7M |
| 2024-06-21 | Campbell Shannon | Director | Grant | 2K | $4.98 | $10K | 2K |
| 2024-06-21 | Raman Prakash | Director | Grant | 2K | $4.98 | $11K | 2K |
| 2024-06-21 | Behbahani Ali | Director | Grant | 3K | $4.98 | $14K | 55K |
| 2024-03-15 | DIXON WENDY L | Director | Grant | 3K | $4.54 | $15K | 38K |
| 2024-03-15 | Behbahani Ali | Director | Grant | 3K | $4.54 | $14K | 52K |
| 2023-12-15 | DIXON WENDY L | Director | Grant | 4K | $2.73 | $11K | 35K |
| 2023-12-15 | Behbahani Ali | Director | Grant | 4K | $2.73 | $12K | 49K |
| 2023-10-17 | BIOTECH GROWTH N V | TenPercentOwner | Buy | 400K | $2.34 | $936K | 8.5M |
| 2023-09-15 | DIXON WENDY L | Director | Grant | 3K | $3.60 | $11K | 31K |
| 2023-09-15 | Velleca Mark A. | PRESIDENT & CEO | Grant | 5K | $3.60 | $19K | 47K |
| 2023-09-15 | Behbahani Ali | Director | Grant | 3K | $3.60 | $12K | 44K |
| 2023-07-05 | Behbahani Ali | Director | Buy | 1.0M | $5.00 | $5.0M | 4.4M |
| 2023-07-05 | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | 936K | $5.00 | $4.7M | 3.2M |
| 2023-06-30 | BB BIOTECH AG | TenPercentOwner | Buy | 1.0M | $5.00 | $5.0M | 8.1M |
| 2023-06-27 | Epstein David M. | SEE REMARKS | Sell | 25K | $6.70 | $168K | 671K |
| 2023-06-27 | BIOTECH GROWTH N V | TenPercentOwner | Buy | 1.7M | $5.49 | $9.6M | 7.1M |
| 2023-06-16 | Velleca Mark A. | Director | Grant | 9K | $2.10 | $19K | 41K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON2 holders report 5% or more of BDTX in their latest filing, all on Schedule 13G (passive). The largest reported stake is T. Rowe Price Investment Management, Inc. at 7.0% of the class (4,028,202 shares), filed 2026-07-08 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-07-27 | 13G | BlackRock, Inc.parent holding company | 3.8M | 6.7% | 2026-06-30 |
| 2026-07-08 | 13G/Ano. 4 | T. Rowe Price Investment Management, Inc.investment adviser | 4.0M | 7.0% | 2026-06-30 |
| 2026-02-17 | 13G/Ano. 1 | Vestal Point Capital, LPinvestment adviser, partnership | 870K | 1.5% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Ryan Wilderparent holding company, individual | 870K | 1.5% | 2025-12-31 |
13F holders
Tracked managers holding BDTX at their latest 13F. JSON3 of the 30 tracked managers held BDTX at their latest 13F, $4.0M in total at quarter-end prices. Renaissance Technologies is the largest at $3.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 2.0M | $3.6M | 0.01% | +319K |
| D. E. Shaw & Co. | 2026-06-30 | 157K | $291K | 0.00% | -207K |
| Two Sigma Investments | 2026-06-30 | 42K | $78K | 0.00% | -1K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated $29.6M of operating cash flow.
- Cash
- $19.2M
- Equity
- $96.1M
- Total assets
- $125.0M
- Shares outstanding
- 57,453,747
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | n/a | -$9.9M | n/a | -0.17 |
| Q1 FY 2026 | 2026-03-31 | n/a | -$9.0M | n/a | -0.16 |
| Q4 FY 2025derived | 2025-12-31 | n/a | -$15.1M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | n/a | -$8.5M | n/a | -0.15 |
| Q2 FY 2025 | 2025-06-30 | n/a | -$10.6M | n/a | -0.19 |
| Q1 FY 2025 | 2025-03-31 | n/a | $56.5M | n/a | 0.98 |
| Q4 FY 2024derived | 2024-12-31 | n/a | -$16.0M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | n/a | -$15.6M | n/a | -0.28 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | n/a | $22.4M | $29.6M | n/a | n/a | n/a |
| FY 2024 | 2024-12-31 | n/a | -$69.7M | -$62.3M | $0 | n/a | n/a |
| FY 2023 | 2023-12-31 | n/a | -$82.4M | -$66.7M | $33K | n/a | n/a |
| FY 2022 | 2022-12-31 | n/a | -$91.2M | -$85.1M | $192K | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | -$125.6M | -$100.1M | $2.7M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-30 from the cover page.
What this page is
Black Diamond Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Black Diamond Therapeutics (BDTX), SEC CIK 1701541, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-10.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-07-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-18.JSON and CSV
- Company record
- EDGAR filing index for CIK 1701541Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
- MRNAModerna
- TWSTTwist Bioscience
- ADPTAdaptive Biotechnologies
- NVAXNovavax
- RXRXRecursion Pharmaceuticals
- DNAGinkgo Bioworks Holdings
- PCVXVaxcyte
- NBIXNeurocrine Biosciences
- VIRVir Biotechnology
- EXELExelixis
- RVMDRevolution Medicines
- GILDGilead Sciences
- HALOHalozyme Therapeutics
- KYMRKymera Therapeutics
- AMGNAmgen
- KRYSKrystal Biotech
- RGENRepligen
- VCELVericel
- BIIBBiogen
- CRSPCRISPR Therapeutics
- DNLIDenali Therapeutics
- KODKodiak Sciences
- TECHBio-Techne
- BEAMBeam Therapeutics
Datasets
Frequently Asked Questions
How much of BDTX is sold short?
What is BDTX's daily short volume?
Does BDTX have fails to deliver?
Are BDTX insiders buying or selling?
Who owns 5% or more of BDTX?
What did BDTX report last quarter?
Which tracked 13F managers own BDTX?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.